462 related articles for article (PubMed ID: 34626362)
1. Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).
Shouse G; Budde E; Forman S
Cancer Treat Res; 2021; 181():179-196. PubMed ID: 34626362
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
3. Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
Agrawal V; Murphy L; Pourhassan H; Pullarkat V; Aldoss I
Eur J Haematol; 2024 Feb; 112(2):236-247. PubMed ID: 37772976
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
5. INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia.
Lamble AJ; Moskop A; Pulsipher MA; Maude SL; Summers C; Annesley C; Baruchel A; Gore L; Amrolia P; Shah N
Transplant Cell Ther; 2023 Nov; 29(11):674-684. PubMed ID: 37689393
[TBL] [Abstract][Full Text] [Related]
6. Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?
Marinos A; Heslop HE
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101414. PubMed ID: 36517124
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
Gauthier J; Turtle CJ
Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
10. [Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia].
Takahashi Y; Nishio N
Rinsho Ketsueki; 2023; 64(9):1184-1191. PubMed ID: 37899199
[TBL] [Abstract][Full Text] [Related]
11. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Gupta S; Kohorst M; Alkhateeb HB
Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
[TBL] [Abstract][Full Text] [Related]
12. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
14. An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia.
Laetsch TW; Yanik GA; Boyer MW; Rheingold SR
Blood Rev; 2021 Nov; 50():100848. PubMed ID: 33994222
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
Summers C; Wu QV; Annesley C; Bleakley M; Dahlberg A; Narayanaswamy P; Huang W; Voutsinas J; Brand A; Leisenring W; Jensen MC; Park JR; Gardner RA
Transplant Cell Ther; 2022 Jan; 28(1):21-29. PubMed ID: 34644605
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
19. Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report.
Deng L; Xiaolin Y; Wu Q; Song X; Li W; Hou Y; Liu Y; Wang J; Tian J; Zuo X; Zhou F
Front Immunol; 2022; 13():1039929. PubMed ID: 36466893
[TBL] [Abstract][Full Text] [Related]
20. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
